Aurobindo receives FDA approval for ritonavir tablets

Print Friendly, PDF & Email

EAST WINDSOR, N.J. — Pharma Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for ritonavir tablets USP, 100 mg. Aurobindo’s ritonavir tablets are an AB-rated generic equivalent to the reference listed drug, AbbVie Inc.’s Norvir.

Ritonavir is in a class of medications called protease inhibitors. Protease inhibitors are effective at decreasing the amount of HIV in the bloodstream by preventing new (immature) HIV from becoming a mature virus that infect other white blood cells. Although, ritonavir cannot cure HIV, it may decrease the chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses.


Adheris Health

Comments are closed.

Adheris Health